Strota/ Newsroom/ 2026-08-11

GLAND surged +9.6% on volume spike 39.0x

Strota Newsroom · session of 2026-08-11 · market close · GLAND stock page →

Gland Pharma Ltd. (GLAND) surged +9.6% to ₹2,924.40 with 4 signals firing. Here is what the exchange data shows.

Gland Pharma closed at ₹2,924.40, up 9.64%, most of it banked at the open. The stock started 6.68% above the previous close of ₹2,667.30 and never handed the ground back, ranging between ₹2,808 and ₹2,988.40 before settling a little under the peak. The close sat 0.94% above the session's VWAP, the average level at which the day's shares changed hands, so buyers held the upper hand well past the opening auction. The Nifty went the other way, down 0.46%.

On derivatives there is nothing to report, and that is a gap in the record rather than a finding. The futures and options positioning field is null, not flat, so the pack cannot say whether the move came with fresh long positions in futures, with shorts being bought back, or with no derivatives involvement at all.

Institutional and insider activity is quiet for the opposite reason: those records exist and are empty. No bulk or block deals were logged at the counter today or over the past thirty days, no insider filings in the past sixty, and no streak of institutional buying or selling is attached to the name.

Volume is where the day's fingerprints are clearest, and also where the pack argues with itself. One signal describes a volume spike of 39.0 times the usual; the relative-volume reading in the technicals section puts it at 19.63 times. Both readings are extraordinary; they do not reconcile.

The technical picture is stretched. The 14-day RSI, a momentum gauge, stood at 78.5, well inside what is conventionally called overbought territory. The close was 2.14% below the 52-week high and 85.84% above the 52-week low, above both the 50-day and 200-day moving averages, and the stock passes the trend-template screen. It has added 13.2% in a week and 18.8% in a month. No golden cross, death cross or Darvas breakout was flagged, so the day extended a climb already under way rather than starting one.

The news flow points one way. Reuters reported that the company had beaten profit expectations for the quarter on the strength of European and US sales, and CNBC TV18 reported first-quarter net profit higher by 47% and revenue up 20%, crediting the CDMO and B2B businesses. Both landed about a day before this session, fitting the gap-up open. Intraday, HDFC Sky and Moneycontrol reported the stock jumping 12% on the results and on broker upgrades, Moneycontrol attributing an upgrade to Jefferies, while Business Standard noted the volumes. Those are headlines, not filings, and the 12% they describe was an intraday level the stock did not hold into the close.

The catalyst is unusually legible: the quarterly numbers and the broker response, endorsed hard enough to lift the stock on a day the index fell. What the data does not establish is who was on the other side. With no derivatives footprint, no deals and no insider filings, there is no way to separate durable buying from fast money, and an RSI of 78.5 alongside a price barely two per cent under its 52-week high describes a stock that has already travelled a long way.

The numbers

Signals that fired

Technical context

Volume ran at 19.6× its 20-day average; rsi(14) sits at 78; price is 2.1% from the 52-week high; trading above the 50-dma and 200-dma.

Recent headlines

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.